1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Samil Pharmaceutical Co., Ltd.

Samil Pharmaceutical Co., Ltd.

KKRX:000520
8,230.00
KRW
+100.00
(+1.23%)
-1,767.70EPS
141.05BMarket Cap
Samil Pharmaceutical Co., Ltd.
KRX:000520
(Korea Stock Exchange)

Recent

price

8,230.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
8,240
7,959.67
7,701.37
7,517.42
7,289.92
7,566.8
8,340.96
7,915.88
8,140.25
9,031.74
9,147.38
9,701.02
11,548.9
13,691.36
12,216.8
9,905
9,744.91
Revenue per Share
171.31
-571.11
-244.22
668.09
-954.48
50.51
76.43
-108.93
-736.82
58.64
99.7
-386.36
-1.82
116
-313
-1,633
-1,767.7
Basic EPS, GAAP
-931.65
-798.69
251.51
-494.73
-1,510.46
32.96
101.88
-3,401.43
-562.56
-290.14
-701.77
-2,288.84
-2,860.44
-881.75
-168.05
-327.64
-118.28
Free Cash Flow per Basic Share
90.03
- -
65.86
65.89
66.71
87.63
87.99
65.84
65.87
45.52
68.34
67.83
64.35
- -
- -
- -
- -
Dividend per Share
6,007.51
5,611.45
5,297.17
5,899.83
4,769.4
4,682.91
4,550.42
4,403.8
4,176.66
4,620.6
4,616.27
4,776.06
8,830.45
8,838.31
8,296.13
6,277.17
5,874.9
Book Value per Share
5,866.48
5,039.46
4,761.83
5,474.31
4,597.53
4,510.12
4,373.56
4,268.96
4,059.62
4,492.15
4,490.9
4,681.97
8,610.32
8,643.42
8,036.5
6,018.98
5,622.68
Tangible Book Value per Share
12
12
12
12
12
12
12
12
12
13
13
14
16
14
18
21
21
Basic Weighted Avg Shares
98,334
94,476
91,444
89,229
85,461
88,136
96,758
92,038
94,600
121,107
122,999
134,247
179,676
196,346
219,700
210,253
207,329
Sales/Revenue/Turnover
0.56
-9.28
-1.72
-2.22
-10.08
1.82
3.98
1.42
-6.06
3.98
5.32
0.3
2.24
3.3
0.05
-10.56
-13.71
Operating Margin (%)
3,518
3,651
3,641
3,528
3,412
3,039
3,147
3,643
3,686
4,016
4,199
4,712
4,989
5,368
7,263
9,197
9,458
Depreciation Expense
2,044
-6,779
-2,900
7,930
-11,190
588
887
-1,267
-8,563
786
1,341
-5,347
-28
1,664
-5,629
-34,664
-37,609
Net Income, GAAP
39.2
- -
- -
35.14
- -
44.14
66.77
- -
- -
45.98
- -
- -
102.67
- -
- -
- -
- -
Effective Tax Rate (%)
2.08
-7.18
-3.17
8.89
-13.09
0.67
0.92
-1.38
-9.05
0.65
1.09
-3.98
-0.02
0.85
-2.56
-16.49
-18.14
Profit Margin (%)
20,213
6,285
24,595
30,035
20,381
14,292
12,768
-252
-26,136
11,044
-26,160
-44,964
-57,811
-87,560
-15,314
-103,204
-84,155
Working Capital
10,000
- -
7,000
- -
8,000
- -
2,000
27,000
- -
45,280
20,307
32,914
73,304
50,794
86,048
22,836
52,285
LT Debt
71,305
66,604
62,874
70,027
55,415
54,410
52,871
51,167
56,083
62,272
63,551
65,746
125,820
127,827
176,124
133,262
125,550
Total Equity
0.32
- -
- -
-1.33
- -
1.03
1.54
- -
- -
1.87
- -
- -
-0.04
- -
- -
- -
- -
Return on Invested Capital (%)
3.07
- -
- -
9.33
- -
1.45
1.51
- -
- -
2.08
- -
- -
-0.06
- -
- -
- -
- -
Return on Capital (%)
2.9
-9.83
-4.48
11.93
-17.84
1.07
1.65
-2.43
-15.97
1.33
2.13
-8.27
-0.03
1.31
-3.7
-22.41
-27.37
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
141,187
118,171
123,761
LT Borrowings
21,614
46,765
51,138
LT Finance Leases
1,222
1,090
1,147
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
205,715
196,610
141,046

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
81,958
74,733
76,248
Cash, Cash Equivalents & STI
6,412
1,188
6,104
Accounts Receivable, Net
35,417
35,518
33,062
Inventories
34,833
32,887
31,756
Total Current Liabilities
185,163
163,729
160,403
Payables & Accruals
- -
- -
- -
ST Debt
141,187
118,171
123,761
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.65%
21.97%
-24.34%
Free Cash Flow
-296.14%
51.72%
130.12%
Net Income, GAAP
-615.66%
-1,300.35%
515.83%
Sales/Revenue/Turnover
9.71%
11.97%
-4.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54,299
54,288
53,322
57,791
219,700
2025
52,288
53,786
51,176
53,004
210,253
2026
52,547
50,602
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-118
21
-39
-167.71
-313
2025
-428
-306
-373.3
-525.68
-1,633
2026
-509.07
-360
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Samil Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products primarily in South Korea with international operations in Vietnam, Canada, and Japan. Founded in 1947 and headquartered in Seoul, the company offers a broad portfolio of prescription and over-the-counter medicines including hepatic and gastrointestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes, and laxatives under brands like Plybutine and Gliptide; antipyretic, analgesic, and anti-inflammatory agents under Brufen; nutritional supplements comprising vitamins, minerals, and immunosuppressants; circulatory drugs including vasodilators and antithrombotics; respiratory, antibiotic, neurological, metabolic, antihistamine, hormone, anti-tumor, urinary, and ophthalmic preparations such as artificial tears; skeletal muscle relaxants; gout and anti-parkinsonism agents; as well as OTC products, sanitary aids, dental preparations, disinfectants, and amino acids. Samil Pharmaceutical specializes in ophthalmology with partnerships including Allergan (AbbVie), Thea Pharma, and Samsung Bioepis for ranibizumab biosimilars, while expanding into contract development and manufacturing organization (CDMO) services focused on preservative-free eye drops and customized manufacturing. In September 2024, its Vietnam facility in Ho Chi Minh City's Saigon Hi-Tech Park received Good Manufacturing Practice certification from the Vietnam Drug Administration, enabling production of up to 300 million eye drop doses annually using advanced Blow-Fill-Seal and multi-filler equipment for global clients. The company entered strategic partnerships in June 2025 with SK Biopharmaceuticals and SK Networks' PhnyX Lab to develop Cheiron Write, an AI platform automating medical writing for drug development workflows, and holds exclusive South Korean rights to Biosplice Therapeutics' Lorecivivint, a Phase 3 knee osteoarthritis candidate with positive long-term trial data announced in December 2024.